Close Menu
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
What's Hot

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Facebook X (Twitter) Instagram
subjectional.com
Subscribe
  • Home
  • Vaccines
  • Politics
  • Health
  • Tech
  • Sports
  • Research
  • Fitness
  • Careers
subjectional.com
Home » New COVID variant XEC spreading in Europe: What you need to know
Vaccines

New COVID variant XEC spreading in Europe: What you need to know

Paul E.By Paul E.September 25, 2024No Comments3 Mins Read
Share Facebook Twitter Pinterest Copy Link Telegram LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


Key Takeaways

The new COVID-19 variant, XEC, is spreading rapidly in Europe and may soon become the dominant variant worldwide. XEC is a recombinant variant composed of two JN.1-related strains. A CDC spokesperson said current COVID-19 vaccines are expected to provide some protection against XEC and other circulating variants.

A new COVID-19 variant called XEC is spreading rapidly in Europe.

According to researchers at the University of Glasgow, XEC is better at growing than other circulating variants and “has the potential to become the dominant variant globally within the next few months.”

Although several cases of XEC have been reported in the United States, the Centers for Disease Control and Prevention (CDC) has not yet begun tracking the new variant.

According to Dr. Andrew Pecos, professor and associate dean of molecular microbiology and immunology at the Johns Hopkins Bloomberg School of Public Health, XEC is a “recombinant” variant made up of two JN.1-related variants (KS.1.1 and KP.3.3).

The new variant’s spike protein – the part of the virus that enters human cells and causes infection – is related to JN.1 and KP.2, which are the targets of the latest COVID vaccines.

“The match isn’t perfect,” Pecos said, “but it’s close enough for scientists to be confident that the vaccine will provide significant protection.”

Pecos added that COVID-19 does not appear to be a seasonal disease like influenza, even though a COVID-19 vaccine is released each fall. “We are seeing high numbers of COVID-19 cases year-round,” he said.

The variants that are emerging are all related to the Omicron variant, and Dr. Harish Moorjani, an infectious disease specialist at Phelps Hospital in Briar Cliff Manor, New York, said having a previous Omicron infection and getting vaccinated could potentially protect you from getting severe COVID.

CDC spokesperson Melissa Brower Dibble said the agency is recommending COVID-19 vaccination for everyone 6 months of age and older in 2024-2025 to protect against XEC and other variants.

At this time, Brower-Dibble said, “We expect that COVID-19 treatments and vaccines will continue to be effective against all circulating variants. CDC will continue to monitor the effectiveness of treatments and vaccines against circulating variants.”

What this means for you

XEC is spreading rapidly, but current vaccines are hopeful that they may be protective. Stay up to date on your COVID-19 vaccination to reduce your risk of severe COVID.

The information in this article is current as of the date stated, but more recent information may be available by the time you read this article. For the latest information on COVID-19, visit our coronavirus news page.

By Fran Kritz

Critz is a medical reporter specializing in health policy. She was previously a staff writer for Forbes and U.S. News & World Report.

Thank you for the feedback!

What’s your feedback?

Other useful error reports



Source link

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Copy Link
Previous ArticleSedgwick County promotes COVID and flu vaccinations
Next Article OHC Symposium Focuses on Rare Disease Research and Treatment
Paul E.
  • Website

Related Posts

Kentucky leaders emphasize whooping cough vaccination

October 31, 2024

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial

October 31, 2024

Trust is important, but increasing vaccination rates also requires three things

October 31, 2024
Leave A Reply Cancel Reply

Latest Posts

Health Canada approves Novartis’ KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence

Sheriff, county lawyer seeking mental health funds at Minnesota State Capitol

Chronic absences have not disappeared. Research shows that poor children are most hurt.

Transport Secretary reveals overhaul of aging pneumatic transport systems

Latest Posts

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Welcome to Subjectional!

At Subjectional, we believe that informed opinions are the foundation of a vibrant society. Our mission is to provide insightful, engaging, and balanced information across a diverse range of topics that matter to you. Whether you’re interested in the latest developments in health, navigating the complexities of politics, staying updated on sports, exploring technological advancements, or advancing your career, we’ve got you covered.

Facebook X (Twitter) Instagram Pinterest YouTube

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Facebook X (Twitter) Instagram Pinterest
  • Home
  • About Us
  • Advertise with Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2025 subjectional. Designed by subjectional.

Type above and press Enter to search. Press Esc to cancel.